Advertisement

Dose dependency of earthworm powder on antithrombotic and fibrinolytic effects

  • Yeong Shik Kim
  • Mi Kyung Pyo
  • Kyung Mi Park
  • Bum Soo Hahn
  • Kyung Youl Yang
  • Hye Sook Yun-Choi
Research Articles

Abstract

The freeze-dried powder ofLumbricus rubellus earthworm was administered orally to rats and its fibrinolytic and antithrombotic effects were investigated. The fibrinolytic activity of plasma was determined by measuring the plasmin activity of the euglobulin fraction and was increased to two-folds of the control at a dose of 0.5g/kg/day and five times with 1 g/kg/day after 4-day administration. The antithrombotic effect was studied in an arterio-venous shunt model of rats. The thrombus weight decreased significantly from 43.2 mg to 32.4 mg at a dose of 0.5g/kg/day after 8-day treatment. The level of fibrinogen/fibrin degradation product (FDP) in serum was elevated in a dose-dependent manner during the treatment period. On the 8th day after administration, the FDP value was increased to 7.7 μg/ml compared with the control value of 3.3 μg/ml. These results support that earthworm powder is valuable for the prevention and/or treatment of thrombotic conditions.

Key words

Lumbricus rubellus earthworm powder Antithrombotic activity Fibrinolytic activity Arterio-venous shunt model 

References Cited

  1. Becker, R., Seminars in thrombosis, thrombolysis, and vascular biology: IV, Fibrinolysis.Cardiology, 79, 188–210 (1991).PubMedCrossRefGoogle Scholar
  2. Chang, C. S., Lee, C. K., Shin, J. S., Cho, I. H. and Suh, J. J., Fibrinolytic and anticoagulant effects of earthworm,Lumbricus rubellus, extracts.Yakhak Hoeji, 39, 666–670 (1995).Google Scholar
  3. Hahn, B. S., Jo, Y. Y., Yang, K. Y., Wu, S. J., Pyo, M. K., Yun-Choi, H. S. and Kim, Y. S., Evaluation of thein vivo antithrombotic, anticoagulant and fibirnolytic activities ofLumbricus rubellus earthworm powder.Arch. Pharm. Res., 20, 17–23 (1997).PubMedCrossRefGoogle Scholar
  4. Hong, S. Y., Yang, D. H., Oh, D. Y. and Park, S. Y., Lumbrikinase effect on physiologic fibrinolytic effect.Kor. J. Int. Med., 40, 77–83 (1991).Google Scholar
  5. Kim, J. K. and Xiao, P. G., Traditional drugs of the East Asia. Younglim Co., Seoul, pp. 415, 1995.Google Scholar
  6. Mihara, H., Marujama, M. and Sumi, H., Novel thrombolytic therapy discovered from traditional oriental medicine using the earthworm.Southeast Asian J. Trop. Med. Public Helath, 23, 131–140 (1992).Google Scholar
  7. Mihara, H., Sumi, H., Akazawa, K., Yoneta, T., and Mizumoto, H., Fibrinolytic enzyme extracted from earthworm.Thromb. Haemost., 50, 258 (1983).Google Scholar
  8. Mihara, H., Sumi, H., Yoneta, T., Mizumoto, H., Ikeda, R., Seiki, M. and Maruyama, M., A novel fibrinolytic enzymes extracted from the earthworm,Lumbricus rubellus.Jap. J. Physiol., 41, 461–472 (1991).CrossRefGoogle Scholar
  9. Nakajima, N., Ishihara, K., Sugimoto, M., Sumi, H., Mikuni, K., and Hamada, H., Chemical modification of earthworm fibrinolytic enzyme with human serum albumin fragment and characterization of the protease as a therapeutic enzyme.Biosci. Biotech. Biochem., 60, 293–300 (1996).CrossRefGoogle Scholar
  10. Park, S., Kye, K. C., Lee, H. B., Kim. J. S. and Lee, M., Antithrombotic effect of intravenoeous administration of lumbrikinase. An earthworm fibrinolytic enzyme on thrombin-induced thromboembolism in mice.Thromb. Haemost., 65, 1195 (1991).Google Scholar
  11. Sawdey, M. S. and Loskutoff, D. J., Regulation of murine type 1 plasminogen activiator inhibitor gene expressionin vivo.J. Clin. Invest., 88, 1346–1353 (1991).PubMedCrossRefGoogle Scholar
  12. Sumi, H., Hamada, H., Nakanishi, K. and Hiratani, H., Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase.Acta Haematol., 84, 139–143 (1990).PubMedGoogle Scholar
  13. Sumi, H., Toki, N., Sasaki, K. and Toki, N., Oral administration of urokinase.Thromb. Res., 20, 711–714 (1980).PubMedCrossRefGoogle Scholar
  14. Umetsu, T. and Sanai, K., Effect of 1-methyl-2-mercapto-5-(3-pyridy)-imidazole (KC-6141), an anti-aggregation compound, on experimental thrombosis in rats.Thromb. Haemost., 39, 74–83 (1978).PubMedGoogle Scholar
  15. Vassalli, J.-D., Sappino A.-P. and Belin, D., The plasminogen activator/plasmin system.J. Clin. Invest., 88, 1067–1072 (1991).PubMedCrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 1998

Authors and Affiliations

  • Yeong Shik Kim
    • 2
  • Mi Kyung Pyo
    • 2
  • Kyung Mi Park
    • 2
  • Bum Soo Hahn
    • 2
  • Kyung Youl Yang
    • 1
  • Hye Sook Yun-Choi
    • 2
  1. 1.R&D CenterSamsung Fine Chemicals Co.TaejonKorea
  2. 2.Natural Products Research InstituteSeoul National UniversitySeoulKorea

Personalised recommendations